National Institutes of Health (NIH) has identified improving sleep quality as a target for potential therapeutics for Long COVID 6, 7, 8, consistent with the proposed mechanism of TNX-102 SL. Lederman continued, “TNX-102 SL improves sleep quality in fibromyalgia, and we believe this is the mechanism by which TNX-102 SL improves other symptoms, like multi-site pain. In completing this clinical milestone, marked by the last enrolled patient finishing their final visit, we can now begin to look forward to topline results from the 63-patient PREVAIL study later this quarter.”ĭr. We have termed this subgroup, ‘Fibromyalgia-type Long COVID.’ Given our encouraging results with TNX-102 SL as a potential treatment for fibromyalgia 4, we are testing TNX-102 SL as a bedtime medicine for the management of Fibromyalgia-type Long COVID. “In addition to multi-site pain, these individuals often suffer from one or more other symptoms typically associated with fibromyalgia such as fatigue, sleep disturbance, and brain fog. Long COVID patients have fibromyalgia-like multi-site pain symptoms based on our observational studies of Long COVID patients from the TriNetX claims database,” 2, 3 said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. Topline results for the PREVAIL study are expected in the third quarter of 2023. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced the completion of the clinical phase of the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL as a potential treatment for fibromyalgia-type Long COVID. 07, 2023 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp.
Long COVID Afflicts Approximately 19% of Patients Following COVID-19 1, and is Expected to be a Global Health Burdenįibromyalgia-Type Long COVID with Multi-Site Pain Affects Approximately 40% of Long COVID PatientsĬHATHAM, N.J., Aug. Topline Results Expected Third Quarter 2023
0 kommentar(er)
